Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

Cohort study in (n=72) found that median time to remission was shorter for new-onset vs refractory disease (7 vs 16 months: HR 2.53; 95%CI, 1.26-5.07). Findings suggest a greater benefit of rituximab when given earlier in the disease course, but a confirmatory RCT is warranted.

JAMA Neurology